Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem, Inc. (VSTM) – Form 4 insider transaction summary
Chief Financial Officer Daniel Calkins filed a Form 4 reporting two open-market sales of Verastem common stock:
- 06/20/2025: 4,110 shares sold at $5.13 per share.
- 06/23/2025: 25 shares sold at $4.71 per share.
The filing explains that the transactions were executed solely to cover statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs). No derivative securities were involved in this report.
Following the sales, Calkins’ direct beneficial ownership stands at 109,945 common shares. The disposition represents roughly 3.6 % of his previously reported direct holdings, leaving the executive with a substantial equity position that continues to align his interests with shareholders.
No additional purchases, option exercises, or new awards were disclosed, and there is no indication of a 10b5-1 trading plan for these transactions. Because the sales were relatively small and explained as tax-related, the market impact is expected to be limited; however, investors often track insider activity for sentiment cues, and any sale by a senior officer can attract attention.
Verastem, Inc. (VSTM) Form 4 filing: On 06/16/2025, President & CEO and director Dan Paterson reported the sale of 335 shares of Verastem common stock at $5.65 per share. The transaction code “S” indicates an open-market sale, but the footnote clarifies that the shares were sold solely to satisfy statutory tax-withholding obligations arising from recently vested restricted stock units (RSUs).
Following the small disposition, Paterson’s direct ownership stands at 461,647 shares. The sale represents less than 0.1 % of his post-transaction holdings, suggesting no meaningful change in his economic exposure to the company. No derivative security transactions were reported, and there were no indications of additional sales or purchases under a Rule 10b5-1 trading plan. Overall, the filing signals routine administrative activity rather than a strategic shift in insider sentiment.
SEC Form 4 overview – Verastem, Inc. (VSTM)
On 06/16/2025 director Robert E. Gagnon reported the disposition of 284 common shares at $5.65 per share, an aggregate value of roughly $1.6 thousand. The sale was executed solely to satisfy statutory tax-withholding requirements related to the vesting of restricted stock units, according to the filing’s footnote. After the transaction Gagnon directly owns 42,242 shares; no derivative securities were traded or reported. Because the sale represents less than 1% of his holdings and is administrative in nature, the filing signals minimal change in insider alignment and no operational impact on Verastem.